More dispensing after coverage expansion is not itself proof of more inappropriate use or medication harm.
The natural-experiment analysis tracked Ontario benzodiazepine dispensing among people aged twenty-four and younger from 2013 to early 2020. An interrupted time-series model found an immediate increase after OHIP+ implementation. The subsequent coverage modification did not produce a clearly detected change in the monthly trend.
The policy was not randomized, and claims did not establish indication, as-needed versus continuing use or actual ingestion. Other time-varying factors can affect trends. The historical analysis does not describe current eligibility rules.
For interpreting policy evidence, distinguish access, prescribing, dispensing and clinical outcome. Increased access may change recorded supply without identifying misuse or dependence. The study supports a population-level association with coverage design, not a conclusion about the appropriateness or functional effect of an individual prescription.
Source reviewed: Impact of a publicly funded pharmacare program policy on benzodiazepine dispensing among children an (PMC10585894). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Ontario First Nations Dispensing Study Defined a Specific Population and Historical Period.